Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results ANN ARBOR, Mich., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment...

ANSYS, Inc. Reports Q2 2016 Financial Results Highlighting Solid Revenue, Margin and EPS Performance Quarterly Highlights: GAAP and non-GAAP revenue of $246.1 million GAAP diluted earnings per share of $0.78 and non-GAAP diluted earnings per share of $0.93GAAP operating profit margin of 38.3% and...